This case study reports on a patient who relapsed with thymoma (mixed type) nine years after tumor resection. After four courses of rescue chemotherapy (docetaxel and cisplatinum), the patient was further diagnosed with pure red cell aplasia. It was noticed that cyclosporin A (CsA), which was administered to treat aplasia, could reverse chemoresistance. Its mechanism is not completely clear, but the hypothesis of CsA inhibiting P-glycoprotein mediated drug efflux is the most acceptable.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11861DOI Listing

Publication Analysis

Top Keywords

pure red
8
red cell
8
cell aplasia
8
cyclosporin reversed
4
reversed chemoresistance
4
chemoresistance patient
4
patient pure
4
aplasia secondary
4
secondary thymoma
4
thymoma case
4

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Background: Despite recent FDA approvement of disease-modifying treatments that reduce Aβ, the identification of novel therapeutic strategies that could delay the Alzheimer's disease (AD) development are needed. We identified and developed novel small molecule compounds that mildly inhibit mitochondrial complex I (MCI). Chronic treatment with a tool compound CP2 in 4 mouse models of familial AD was efficacious protecting against synaptic dysfunction and memory impairment, improving brain energetics and cognitive performance, reducing levels of human pTau and Ab.

View Article and Find Full Text PDF

Introduction: We present a rare case of long-term survival following metastasectomy for lumbar metastasis with growing teratoma syndrome.

Case Presentation: An 18-year-old man presented with left scrotal mass and lumbago. Alpha-fetoprotein was elevated to 648.

View Article and Find Full Text PDF

Solution combustion synthesis of ZnO doped CuO nanocomposite for photocatalytic and sensor applications.

Sci Rep

January 2025

Department of Mechanical and Industrial Engineering, Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.

ZnO-doped CuO nanocomposites (CuO-ZnO NPs) of 1, 3, and 5 mol% were prepared by the solution combustion method using ODH as a fuel (Oxlyl-hydrazide) at 500 °C and calcining at 1000 °C for two hours and the Structural, photocatalytic, and electrochemical properties were investigated by experimental and theoretical methods. X-ray diffraction (XRD) patterns revealed a crystallite size (D) range of 25 to 31 nm for pure CuO and 1, 3, and 5 mol% CuO-ZnO NPs. According to calculations, the optical energy band gap (Eg) of the NPs is between 2.

View Article and Find Full Text PDF

Pure phycocyanin (PC) hexamers from red algae were first prepared in this research. PC hexamers are helpful for studying the role and mechanism of PCs in energy transfer within phycobilisomes from red algae. The PC hexamers from Polysiphonia urceolata are stable at lower pH (pH 5.

View Article and Find Full Text PDF

Robust low threshold full-color upconversion lasing in rare-earth activated nanocrystal-in-glass microcavity.

Light Sci Appl

January 2025

State Key Laboratory of Luminescent Materials and Devices, and Guangdong Provincial Key Laboratory of Fiber Laser Materials and Applied Techniques, School of Materials Science and Engineering, South China University of Technology, 510640, Guangzhou, China.

Visible light microlasers are essential building blocks for integrated photonics. However, achieving low-threshold (μW), continuous-wave (CW) visible light lasing at room temperature (RT) has been a challenge because of the formidable requirement of population inversion at short wavelengths. Rare-earth (RE)-activated microcavities, featuring high-quality factor (Q) and small mode volume of whispering gallery modes, offer a great opportunity for achieving infrared-to-visible upconversion (UC) lasing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!